https://www.businesswire.com/news/home/20220922005171/en/Metagenomi-Named-an-Endpoints-11-Winner
Metagenomi Named an Endpoints 11 Winner
Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced that it was selected ...
metagenominamedendpointswinner
https://www.financialcontent.com/quote/NQ:MGX
Metagenomi Therapeutics, Inc. - Common Stock (MGX) Stock Price, News, Quote & History |...
The current price of Metagenomi Therapeutics, Inc. - Common Stock (MGX) is 0.8452. Metagenomi, Inc. is a biotechnology company focused on the advancement of...
common stockmetagenomitherapeuticsincmgx